OBJECTIVES: To estimate seroprevalence of 11 high-risk (hr) HPV types and four low-risk (lr) HPV types among 20-64 years old Slovenian women participating in the population-based cervical cancer screening program. METHODS: Serum samples from 3259 women were tested for HPV type-specific antibodies with a multiplexed pseudovirion-based serological assay (PsV-Luminex). RESULTS: Seropositivity for any of the 15 HPV types was 65.7%, any of the 11 hr-HPV types 59.2%, and any of the four lr-HPV types 33.1%. Antibodies against at least one of the four vaccine HPV types (HPV 6, 11, 16, 18) were detected in 40.8% women. Among hr-HPV types, seropositivity was highest for HPV 16 (25.2%) and among lr-HPV types for HPV 6 (19.1%). Age-specific HPV16 seropositivity was highest among 30-39 years old (29.6%) and decreased with increasing age to 14.0% among 60-64 years old. CONCLUSION: The lifetime sexual exposure to genital HPV types is substantial, emphasising the need for HPV vaccination.
OBJECTIVES: To estimate seroprevalence of 11 high-risk (hr) HPV types and four low-risk (lr) HPV types among 20-64 years old Slovenian women participating in the population-based cervical cancer screening program. METHODS: Serum samples from 3259 women were tested for HPV type-specific antibodies with a multiplexed pseudovirion-based serological assay (PsV-Luminex). RESULTS: Seropositivity for any of the 15 HPV types was 65.7%, any of the 11 hr-HPV types 59.2%, and any of the four lr-HPV types 33.1%. Antibodies against at least one of the four vaccine HPV types (HPV 6, 11, 16, 18) were detected in 40.8% women. Among hr-HPV types, seropositivity was highest for HPV 16 (25.2%) and among lr-HPV types for HPV 6 (19.1%). Age-specific HPV16 seropositivity was highest among 30-39 years old (29.6%) and decreased with increasing age to 14.0% among 60-64 years old. CONCLUSION: The lifetime sexual exposure to genital HPV types is substantial, emphasising the need for HPV vaccination.
Authors: Patricia Sadate-Ngatchou; Joseph J Carter; Stephen E Hawes; Qinghua Feng; Taylor Lasof; Joshua E Stern; Tsung-Chieh Jane Fu; Denise A Galloway; Laura A Koutsky; Rachel L Winer Journal: Sex Transm Dis Date: 2016-03 Impact factor: 2.830
Authors: Rachel A Katzenellenbogen; Joseph J Carter; Joshua E Stern; Melinda S Butsch Kovacic; Parinda A Mehta; Sharon L Sauter; Denise A Galloway; Rachel L Winer Journal: Clin Vaccine Immunol Date: 2015-02-04
Authors: Darron R Brown; Xavier Castellsagué; Daron Ferris; Suzanne M Garland; Warner Huh; Marc Steben; Cosette M Wheeler; Alfred Saah; Alain Luxembourg; Se Li; Christine Velicer Journal: Tumour Virus Res Date: 2022-05-04
Authors: A P Ortiz; G Tortolero-Luna; J Romaguera; C M Pérez; D González; C Muñoz; L González; E Marrero; E Suárez; J M Palefsky; G Panicker; E R Unger Journal: Papillomavirus Res Date: 2018-03-16